Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund raised its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 163.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,906 shares of the company’s stock after buying an additional 40,300 shares during the period. New York State Common Retirement Fund’s holdings in Vir Biotechnology were worth $476,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. KBC Group NV lifted its holdings in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after purchasing an additional 5,177 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in Vir Biotechnology during the 4th quarter worth $74,000. Captrust Financial Advisors purchased a new position in Vir Biotechnology during the 3rd quarter worth $118,000. Quarry LP grew its stake in shares of Vir Biotechnology by 901.8% in the 3rd quarter. Quarry LP now owns 17,000 shares of the company’s stock valued at $127,000 after purchasing an additional 15,303 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Vir Biotechnology during the third quarter worth $138,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. Barclays increased their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Finally, Morgan Stanley upgraded shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.67.

Insider Buying and Selling at Vir Biotechnology

In other news, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the sale, the director now owns 708,295 shares of the company’s stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now owns 1,312,391 shares in the company, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,859 shares of company stock worth $326,458. 15.60% of the stock is owned by insiders.

Vir Biotechnology Stock Up 3.5 %

Shares of VIR stock opened at $8.20 on Wednesday. The stock has a market cap of $1.13 billion, a P/E ratio of -2.09 and a beta of 0.64. Vir Biotechnology, Inc. has a fifty-two week low of $6.56 and a fifty-two week high of $14.45. The business has a fifty day simple moving average of $9.48 and a 200-day simple moving average of $8.49.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The company had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).